Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background Previous studies of CF treatments have shown suboptimal adherence, though little has been reported regarding adherence patterns to ivacaftor. Electronic monitoring (EM) of adherence is considered a gold standard of measurement. Methods Adherence rates by EM were prospectively obtained and patterns over time were analyzed. EM-derived adherence rates were compared to pharmacy refill history and self-report. Results 12 subjects (age 6-48 years; CFTR-G551D mutation) previously prescribed ivacaftor were monitored for a mean of 118 days. Overall adherence by EM was 61%(SD=28%) and decreased over time. Median duration between doses was 16.9 hours (IQR 13.9-24.1 hours) and increased over time. There was no correlation between EM-derived adherence and either refill history (84%, r=0.26, p=0.42) or self-report (100%, r=0.40, p=0.22). Conclusions Despite the promising nature of ivacaftor, our data suggest adherence rates are suboptimal and comparable to other prescribed CF therapies, and more commonly used assessments of adherence may be unreliable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195 · cited 3×
“Thus, patients are being undertreated when they are non-adherent and are less likely to attain the benefits seen in prior studies[3-5].”
BackgroundRowe, S. M., Heltshe, S. L., Gonska, T., Donaldson, S. H., Borowitz, D., Gelfond, D., Sagel, S. D., Khan, U., Mayer-Hamblett, N., Van Dalfsen, J. M., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201404-0703oc · Cited by 492
Adherence to Pediatric Medical Regimens
Rapoff, M. A. (2010) · Issues in Clinical Child Psychology · doi:10.1007/978-1-4419-0570-3 · Cited by 219
Adherence with tobramycin inhaled solution and health care utilization
Briesacher, B. A., Quittner, A. L., Saiman, L., Sacco, P., Fouayzi, H., & Quittell, L. M. (2011) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-11-5 · Cited by 95 · cited 1×
“Multiple studies have shown that higher adherence has been associated with fewer and shorter hospitalizations and less pulmonary exacerbations[10-12].”
BackgroundBall, R., Southern, K. W., McCormack, P., Duff, A. J. A., Brownlee, K. G., & McNamara, P. S. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2012.12.012 · Cited by 53 · cited 1×
“This finding is in line with a recent study of 24 adolescents with CF that revealed an overall adherence rate of 65% ± 28% to nebulized medications using EM data[18].”
ResultAdherence to dornase alfa treatment among commercially insured patients with cystic fibrosis
Nasr, S. Z., Chou, W., Villa, K. F., Chang, E., & Broder, M. S. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.787427 · Cited by 44 · cited 1×
“Multiple studies have shown that higher adherence has been associated with fewer and shorter hospitalizations and less pulmonary exacerbations[10-12].”
Background
Cited by
CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Hisert, K. B., Heltshe, S. L., Pope, C., Jorth, P., Wu, X., Edwards, R. M., Radey, M., Accurso, F. J., Wolter, D. J., Cooke, G., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1954oc · Cited by 389
CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis
Balfour-Lynn, I. M., & King, J. A. (2022) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2020.05.002 · Cited by 85
“This adjustment is not unreasonable given the data from a small study using electronic monitoring that showed an overall adherence to ivacaftor of 61% which decreased over time [9].”
Kirwan, L., Fletcher, G., Harrington, M., Jeleniewska, P., Zhou, S., Casserly, B., Gallagher, C. G., Greally, P., Gunaratnam, C., Herzig, M., et al. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201802-149oc · Cited by 58
The impact of CFTR modulator therapies on CF airway microbiology
Rogers, G. B., Taylor, S. L., Hoffman, L. R., & Burr, L. D. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.07.008 · Cited by 52
Hoo, Z. H., Curley, R., Campbell, M. J., Walters, S. J., Hind, D., & Wildman, M. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s105530 · Cited by 27
“10,11,14 In CF, tamper-proof nebulizer systems which provide date-and time-stamped data for nebulized medication delivered are now available.”
Airway clearance and exercise for people with cystic fibrosis: balancing longevity with life
Rowbotham, N. J., & Daniels, T. E. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.25734 · Cited by 16
Metadata
- Authors
- Siracusa, C. M., Ryan, J., Burns, L., Wang, Y., Zhang, N., Clancy, J. P., & Drotar, D.
- Venue
- Journal of Cystic Fibrosis
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 14
- Issue
- 5
- Pages
- 621-626
- ISSN
- 1569-1993 (ISSN-L)
- OpenAlex
- W2137956968
- Cited by
- 71
- References
- 6
- FWCI
- 7.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.